Corbus outlines phase 1 results from ADC trial for bladder, cervical cancers


Urinary bladder cancer with organs and tumors or cancerous cells 3D rendering illustration with male body. Anatomy, oncology, biomedical, disease, medical, biology, science, healthcare concepts.

libre de droit

Corbus Pharmaceuticals (NASDAQ:CRBP) said that its antibody drug conjugate, CRB-701, demonstrated promising efficacy and safety data in a phase 1 trial.

Patients in the study, which took place in China, had Nectin-4 positive urothelial or cervical cancer and had failed or were

Source link

Leave A Reply

Your email address will not be published.